07:34 AM EDT, 03/24/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Monday it has agreed to pay up to $2 billion for the exclusive rights for a triple receptor agonist in early-stage clinical development for the treatment of obesity, type 2 diabetes and other diseases.

Under the terms of the deal, Novo Nordisk ( NVO ) will obtain the worldwide rights -- excluding the Chinese mainland, Hong Kong, Macau and Taiwan -- to develop manufacture and commercialize the drug, called UBT251, from United Biotechnology, which is eligible to receive $200 million upfront and potential milestone payments of up to $1.8 billion.